Rayner’s clear vision for the future of cataract surgery

Article

Rayner designs and manufactures IOLs and proprietary injection devices for use in cataract surgery. As the first manufacturer of the IOL, they’ve been working with surgeons for longer than anyone.

Rayner designs and manufactures IOLs and proprietary injection devices for use in cataract surgery. As the first manufacturer of the IOL, they’ve been working with surgeons for longer than anyone.

Today, Rayner are bringing new impetus to this focus with the opening of The Ridley Innovation Centre, a new £20million R&D, training and production facility in Worthing, West Sussex, United Kingdom. This IOL production facility has the capability of manufacturing 3 million intraocular lenses each year.

In addition, their new Enterprise Resource Planning (ERP) quality system enables them to trace every lens from source materials to a patient’s eye. What’s more, Rayner is the only IOL manufacturer in the UK and their investment represents commitment to delivering competitive high quality technology from a well-trained UK manufacturing team.

Their mission statement is to “exist to enable surgeons to focus on what matters: improving patient’s sight. We aim to remain at the forefront of innovation, developing clinically superior ophthalmic tools that aid and streamline the surgical process, with the ultimate objective of improving sight and quality of life.”

Furthermore, Rayner’s aim has always been to provide cataract surgeons with high-quality, innovative and simple solutions which enable superior patient outcomes.

New centre

 


The new centre was also designed with the surgeon at its heart to enable training, education and research. Featuring a wet lab, library, training facilities and even a museum on the history of the IOL, this enables Rayner to engage and partner surgeons and academics in new product development.

Testament to this culture is a product pipeline of 11 new products in 3 years planned to transform Rayner into one of the leading manufacturers of IOLs.

Tim Clover, CEO, explains the significance of the new building: “The opening of The Ridley Innovation Centre marks a significant step in what we plan to be an exciting, transformative period of growth ahead of Rayner. This major investment will treble our manufacturing capacity and put us in the best position to support the company’s ambitious business expansion.

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Recent Videos
Omer Trivizki, MD, MBA, a retina specialist from Tel Aviv Medical Center, speaks about VOY-101, a Novel, Complement-Modulating Gene Therapy for Geographic Atrophy at the American Society of Retina Specialists (ASRS) Annual Meeting
João Pedro Marques, MD, MSc, PhD discusses a retrospective study of 800 patients with inherited retinal diseases during the American Society of Retina Specialists (ASRS) annual meeting
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
© 2025 MJH Life Sciences

All rights reserved.